TNF receptor superfamily member 21Genealiases: BM-018 · CD358 · DR6
Q-omics provides the consensus-scored TNFRSF21 profile across patient tissues and cancer cell-line models. TNFRSF21 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TNFRSF21 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, TNFRSF21 RNA expression shows 18,569 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUAD, and UVM as cancer lineages where TNFRSF21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFRSF21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFRSF21 survival associations across molecular data types. TNFRSF21 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFRSF21 RNA expression–survival associations across cancer types. High TNFRSF21 expression shows unfavorable associations in UVM, BRCA, LIHC and PAAD, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TNFRSF21 RNA expression.
This table summarizes TNFRSF21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for TNFRSF21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFRSF21 shows higher tumor expression in LUAD, THCA, LUSC, LIHC, STAD and UCEC. The LUAD box plot shows higher TNFRSF21 RNA expression in tumor versus normal tissue (log2 FC = +2.300, t-test p < 0.001).
This table shows molecular features associated with TNFRSF21 in patient tissues and cancer cell lines. In patient samples, TNFRSF21 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFRSF21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
